Kura Oncology Stock Climbs After Early Kidney Cancer Data Shows Activity
Kura Oncology shares rose 9% on Friday after the company disclosed preliminary subset results from its FIT-001 trial showing activity of a darlifarnib and cabozantinib combination in clear cell renal cell carcinoma patients previously treated with cabozantinib. The analysis of 16 patients showed a 44% objective response rate, a 94% disease control …